Search This Blog




Breakthrough: Israel is Developing Cancer Vaccine

: Vaxil’s groundbreaking therapeutic vaccine, developed in Israel, could keep about 90 percent of cancers from coming back.
As the world’s population lives longer than ever, if we don’t succumb to heart disease, strokes or accidents, it is more likely that cancer will get us one way or another. Cancer is tough to fight, as the body learns how to outsmart medical approaches that often kill normal cells while targeting the malignant ones.
Hadassah HospitalIn a breakthrough development, the Israeli company Vaxil BioTherapeutics has formulated a therapeutic cancer vaccine, now in clinical trials at Hadassah University Medical Center in Jerusalem. If all goes well, the vaccine could be available about six years down the road, to administer on a regular basis not only to help treat cancer but in order to keep the disease from recurring.
The vaccine is being tested against a type of blood cancer called multiple myeloma. If the substance works as hoped — and it looks like all arrows are pointing that way — its platform technology VaxHit could be applied to 90 percent of all known cancers, including prostate and breast cancer, solid and non-solid tumors.
“In cancer, the body knows something is not quite right but the immune system doesn’t know how to protect itself against the tumor like it does against an infection or virus. This is because cancer cells are the body’s own cells gone wrong,” says Julian Levy, the company’s CFO. “Coupled with that, a cancer patient has a depressed immune system, caused both by the illness and by the treatment.”
The trick is to activate a compromised immune system to mobilize against the threat.
A vaccine that works like a drug
A traditional vaccine helps the body’s immune system fend off foreign invaders such as bacteria or viruses, and is administered to people who have not yet had the ailment. Therapeutic vaccines, like the one Vaxil has developed, are given to sick people, and work more like a drug.
Vaxil’s lead product, ImMucin, activates the immune system by “training” T-cells –– the immune cells that protect the body by searching out and destroying cells that display a specific molecule (or marker) called MUC1. MUC1 is typically found only on cancer cells and not on healthy cells. The T-cells don’t attack any cells without MUC1, meaning there are no side effects unlike traditional cancer treatments. More than 90% of different cancers have MUC1 on their cells, which indicates the potential for this vaccine.
“It’s a really big thing,” says Levy, a biotechnology entrepreneur who was formerly CEO for Biokine Therapeutics. “If you give chemo, apart from the really nasty side effects, what often happens is that cancer becomes immune [to it]. The tumor likes to mutate and develops an ability to hide from the treatment. Our vaccines are also designed to overcome that problem.”
For cancers in an advanced stage, treatments like chemo or surgery to remove a large tumor will still be needed, but if the cancer can be brought down to scale, the body is then able to deal with it, Levy explains. ImMucin is foreseen as a long-term strategy — a shot every few months, with no side effects — to stop the cancer from reoccurring after initial treatments, by ensuring that the patient’s own immune system keeps it under control.
In parallel, the company is also working on a vaccine that treats tuberculosis, a disease that’s increasing worldwide, including in the developed world, and for which the current vaccine is often ineffective and treatment is problematic.
cancerours cellBased in Ness Ziona, Vaxil was founded in 2006 by Dr. Lior Carmon, a biotechnology entrepreneur with a doctorate in immunology from the Weizmann Institute of Science in Rehovot. In June, Vaxil signed a memorandum of understanding to merge its activities into Sheldonco, a company traded on the Tel Aviv Stock Exchange.
By Rivka Borochov
For more info about this incredible vaccine, visit Vaxil on the web at

聲稱兩年前飛碟門前墜毀 俄婦雪櫃藏「外星人」屍體

星島日報星島日報 – 4小時前





  有網民認為這個「外星人」似足《星球大戰》電影中的赫特人賈巴(Jabba The Hutt)或《捉鬼敢死隊》的為食鬼Slimmer,引起議論紛紛,也有網民揶揄這只不過是一棵腐爛的蔬菜。

  不過,據網站Unexplained Mysteries透露,數日前有兩名男子來到葉戈羅夫南的家,他們聲稱來自俄羅斯科學院的卡里利阿研究中心,把外星人屍體充供進行調查。



清場秘密籌劃兩周 設禁飛區阻報道拘記者

【明報專訊】《紐約時報》引述消息稱,「佔領」大本營祖科蒂公園的清場行動,其實事前秘密籌劃兩周,紐約警方近日安排警員進行密集的人群控制及「反 恐」訓練,務求速戰速決。為防走漏風聲,在正式行動前更只有數名警隊最高層掌握實情,其他警員卻被告知只是例行演習,直至最後一刻才知要執行清場。為免清 場過程公開,警方更鐵腕封鎖傳媒,設禁飛區阻傳媒直升機追訪。
知情人士透露,今次清場由紐約市警察局長凱利 (Raymond Kelly)親自指揮,避免重演上月胡椒噴霧對付示威者的暴力場面,令警隊形象失分。在採取行動前,當局安排警員接受兩周的密集訓練,包括在蘭德爾斯島 (Randalls Island)進行「災難演習」,以便在短時間內動員大量警力。


瑞 士蘇黎世當局亦於周二早上8時驅趕駐紮於市中心林登霍夫公園(Lindenhof Park)的示威者,只給予20分鐘示威者收拾,大部分示威者收拾細軟離開,但有約30示威者和平抗爭到底,最終多人被捕。澳洲墨爾本昨亦有清場行動,警 方周三早上帶走在Treasury Garden的示威者及沒收約10個帳篷。倫敦發通牒驅示威者-212325972.html

美派兵北澳制華 京:不恰當

【明報專訊】正在澳洲訪問的美國總統奧巴馬,與澳洲總理吉拉德昨宣布,兩國達成加強軍事合作協議,為「促進美澳軍事聯盟」,明年中開始將有200至 250名美國海軍陸戰隊隊員在澳洲北部的達爾文港駐紮,每6個月輪流部署,最終將有2500名美軍在澳洲駐守。駐軍安排惹來中國政府關注。中國外交部發言 人劉為民昨說:「(美澳)強化並擴大軍事結盟可能不是很適當,可能也不符合區域內國家的利益」。
根 據駐軍安排,美軍陸戰隊將定期與澳洲部隊進行演習訓練,兩國還同意加強空軍合作,美軍將增加戰機在澳洲北部的輪替。澳洲傳媒更猜測,總理吉拉德日前突然轉 軚,同意向印度出售鈾,是因為受到美國政府的壓力,皆因白宮認為,澳洲拒向印度售鈾,妨礙了美國謀求與印度加強關係牽制中國。但奧巴馬昨堅稱,華府「沒有 施加任何影響力」。美派兵北澳制華-京-不恰當-212325290.html


到 訪坎培拉的美國總統奧巴馬在澳洲國會發表演說,否認美國增加在澳洲的軍力,是應付中國崛起,強調美國放眼未來的亞太地區,美國與其他國家一樣,尋求與中國 有更多合作機會,包括加強軍事溝通,避免誤判形勢。奧巴馬說,亞太是全球經濟增長最快的地區,對美國創造就業起關鍵作用,美國會維持力量在亞太,並同盟友 保持關係,令美國在亞太地區,能夠扮演強大及持久的角色。奧巴馬昨日宣布在澳洲達爾文常駐美軍,被指是要抗衡中國。奧巴馬否認於澳洲駐軍是抗衡中國-004200455.html


土 耳其外交部長達武特奧盧在論壇上發言時對阿盟最近中止敘利亞成員國資格的作法表示支持,並對敘利亞至今未能履行其對人民和阿盟做出的承諾表示遺憾。他強調 「敘利亞政府應該滿足人民的要求,積極回應阿盟提出的解決措施」。他還呼籲國際社會和有關各方為及早結束敘利亞的流血衝突,恢復該國的穩定做出各自的努 力。